14-day Premium Trial Subscription Try For FreeTry Free

Range Low Price High Price Comment
30 days $64.82 $75.66 Wednesday, 24th Apr 2024 CYTK stock ended at $66.82. This is 1.91% more than the trading day before Tuesday, 23rd Apr 2024. During the day the stock fluctuated 2.69% from a day low at $65.68 to a day high of $67.45.
90 days $61.33 $84.05
52 weeks $25.98 $110.00

Historical Cytokinetics prices

Date Open High Low Close Volume
Nov 29, 2023 $31.43 $34.10 $31.43 $32.14 1 772 828
Nov 28, 2023 $31.73 $31.73 $30.68 $31.22 689 082
Nov 27, 2023 $31.87 $32.18 $30.92 $31.83 891 574
Nov 24, 2023 $31.61 $32.20 $31.59 $31.97 380 184
Nov 22, 2023 $32.40 $32.70 $31.46 $31.91 572 301
Nov 21, 2023 $31.70 $32.25 $30.70 $31.74 1 262 581
Nov 20, 2023 $32.67 $33.15 $31.80 $32.31 2 129 983
Nov 17, 2023 $31.95 $32.53 $31.53 $32.44 1 243 394
Nov 16, 2023 $32.78 $33.02 $31.03 $31.68 1 480 165
Nov 15, 2023 $33.63 $35.22 $32.82 $32.83 1 687 308
Nov 14, 2023 $33.38 $34.40 $33.02 $34.29 1 406 379
Nov 13, 2023 $31.84 $33.05 $31.60 $32.01 1 542 389
Nov 10, 2023 $33.12 $33.81 $32.33 $32.50 1 471 780
Nov 09, 2023 $35.40 $35.74 $33.05 $33.11 812 925
Nov 08, 2023 $35.63 $35.76 $34.49 $34.76 921 950
Nov 07, 2023 $35.45 $36.00 $34.91 $35.85 1 254 095
Nov 06, 2023 $35.78 $36.28 $33.61 $34.43 1 456 598
Nov 03, 2023 $35.45 $36.78 $35.01 $36.32 2 029 793
Nov 02, 2023 $35.94 $36.28 $34.58 $34.64 1 605 396
Nov 01, 2023 $34.93 $35.24 $34.21 $35.10 1 913 114
Oct 31, 2023 $31.64 $36.53 $31.46 $34.86 3 752 475
Oct 30, 2023 $31.82 $32.65 $31.50 $32.09 1 649 466
Oct 27, 2023 $32.10 $32.52 $30.37 $31.74 2 348 434
Oct 26, 2023 $33.03 $33.35 $32.27 $32.41 755 983
Oct 25, 2023 $31.44 $33.01 $31.10 $32.59 1 540 721
Click to get the best stock tips daily for free!

About Cytokinetics

Cytokinetics Cytokinetics, Incorporated, a late-stage biopharmaceutical company, focuses on discovering, developing, and commercializing muscle activators and inhibitors as potential treatments for debilitating diseases. The company develops small molecule drug candidates primarily engineered to impact muscle function and contractility. Its drug candidates include omecamtiv mecarbil, a novel cardiac myosin activator that is in Phase III clinical trial in pati... CYTK Profile

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE

ROCKIT